Please find attached the Investor Presentation of the Company

Date: 07-08-2026 To To The General Manager The Manager Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Tower Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Mumbai - 400 051 Ref: BSE Scrip Code: 533259; NSE Symbol: HEALTHX Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation Dear Sir/ Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached herewith the Investor Presentation of the Company. This is for your information and record. Thanking you, Yours faithfully, For Health X Platform Limited (formerly known as Sastasundar Ventures Limited) Pratap Singh Company Secretary & Compliance Officer M. No.: A24081 Encl: As above Health X is India’s AI-powered digital health platform- making medicines, wellness and diagnostics accessible, affordable, and trustworthy from the busiest city to the last village Health X Platform Limited (erstwhile Sastasundar Ventures Limited) August 2026 Safe Harbour Thispresentationandtheaccompanyingslides(the“Presentation”),whichhavebeenpreparedbyHealthXPlatformLimited(erstwhileSastasundar Ventures Limited) (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailedinformationabouttheCompany. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makesnorepresentationorwarranty,expressorimplied,whatsoever,andnorelianceshallbeplacedonthetruth,accuracy,completeness,fairness andreasonablenessofthecontentsofthisPresentation.ThisPresentationmaynotbeallinclusiveandmaynotcontain alloftheinformationthat youmayconsidermaterial.Anyliabilityinrespectofthecontentsof,oranyomissionfrom,thisPresentation isexpresslyexcluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subjecttoknownandunknownrisks,uncertaintiesandassumptionsthataredifficulttopredict.Theserisksanduncertaintiesinclude,butarenot limitedto,theperformanceoftheIndianeconomyandoftheeconomiesofvariousinternationalmarkets,theperformanceoftheindustryinIndia and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward- looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation arenotadoptedbytheCompanyandtheCompanyisnotresponsibleforsuchthird-partystatementsandprojections. Allmaps usedin the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy,timelinessorcompleteness. Key Highlights at a Glance 01 High Revenue Growth Continuous Q-o-Q Y-o-Y Sustained top-line momentum across all channels. ▲16% ▲47% 02 Expanding Gross Margin Gross Margin widening on better sourcing, private-label mix and channel Comparative optimisation. Current Qtr Quarter Change 2A June -26 vs March-26 7.9% 7.5% ▲40bps 2B June -26 vs June-25 7.9% 6.6 % ▲130bps 03 Operating Leverage –Revenue Vs OpexCost Opex falling as a % of revenue; EBIT margin expanding towards Gross Comparative Margin as the fixed-cost base is absorbed by scale. Current Qtr Quarter Change 3A June -26 vs March-26 11.6% 13.3% ▼170bps 3B June -26 vs June-25 11.6% 11.0 % ▲60bps 04 Minimal Depreciation & Finance Cost (Depreciation + Finance Cost) / Revenue Asset-light, low-leverage model keeps Depreciation and finance cost a small 0.7% share of revenue. 05 Working Capital Efficiency Net working-capital days Disciplined receivables, inventory and payables cycle drives strong cash 28days conversion. #Q-o-Q compares the Quarter June-26 with Quarter March -26; Y-o-Y compares the Quarter June-26 with Quarter June -25) *Growth, Gross Margin and Operating Leverage is excluding Financial Services revenue. Philosophies of Capital Allocation Warren Buffett -Real Earnings, Real Discipline HealthX: Where Discipline Meets Patience • Distrusts EBITDA -it ignores real, unavoidable costs like Depreciation “Built on Buffett’s discipline of real, capital-efficient earnings- combined with Bezos’s patience to reinvest in • Measures success through owner earnings: net income (+) the technology, brand, and infrastructure that earns Depreciation and Amortisation(-) the capex needed to stay India’strustinhealthcare”. competitive. • Prizes sustained, low-leverage ROE —capital efficiency proven Discipline: over decades, not one good quarter A capital - efficient, real - earnings mindset across Jeff Bezos -Cash flow and Long-term Compounding SastaSundar and RetailerShakti - every rupee of capitalheldtoaccount. • Prioritizes free cash flow per share over reported GAAP profit as the true measure of value Patience: • Willingly deferred ROCE for years —running thin margins to Sustained reinvestment in technology, brand & fund the flywheel infrastructure -- building the trust that compounds • Reinvested nearly all operating cash into infrastructure, intolong-termmarketposition. logistics, and new bets to build durable market position The HealthX Ecosystem — X-Factor Innovation Value powered by deliveredwith Technology Efficiency Impactdrivenby Trustbuilton Empathy Authenticity Growth Track Record SastaSundar -Pre-FKH SastaSundar –During FKH SastaSundar –Post-FKH ▲68% ▼35% ▲64% 44 44.5 Sales 2014-15 2020-21 2021-22 2024-25 Q4 Q1 Q2 Q3 Q4 Q1 FY25 FY26 FY26 FY26 FY26 FY27 2014-15 2020-21 2021-22 2024-25 Sales (in Crs) 26 32 42 44 44 48 Sales (in Crs) 21 474 Sales (in Crs) 510 135 CAGR* 64 % CAGR* 68% CAGR* 35% Despite recent growth volatility during the partnership with Flipkart, the company successfully leveraged this transition as a strategic opportunity to regain full control. Following Flipkart's decision to streamline its healthcare operations, the partnership ended, resulting in the cessation of Flipkart Health+ as an associate company in FY25. By transitioning from a 25% minority stake back to 100% ownership, the companyisnowfullycapitalizedandideallypositionedwithcompleteoperationalcontrolovertheSastaSundarplatformtodrivefuturescaling. *CAGR Annualized Growth Track Record Retailer Shakti ▲96% 1200 1125 1000 950 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2025-26 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2025-26 Sales (in Crs) 20 66 113 212 489 950 1125 CAGR 96% *CAGR Annualized 15 Capital Efficiency & Working Capital Total Capital Deployed Working Capital Quarter ended Working Capital (No of Days) Jun-26 Mar-26 Jun-25 Mar-25 Amount Particulars (₹ in Crs) Inventory 39 34 36 35 Receivable 3 4 6 7 Total Capital Raised 352 Payable 14 20 11 19 Working Capital (No of Days) 28 18 32 23 Cost of Capital (post-tax) @9% p.aXIRR 431 Working Capital % of Revenue 8% 5% 9% 6% Working Capital ₹ in Crs 128 74 95 73 Total Capital deployed with cost of capital 783 Working Capital Days ↓ 11% YOY Capital Bou [Showing first 8,000 characters — download PDF for full document]